Lipids are considered important factors in the pathogenesis of Alzheimer’s disease (AD). In this study, we realized a comparative analysis of the phospholipid profile and phospholipid composition of the temporal cortex from E280A-familiar AD (FAD), sporadic AD (SAD), and healthy human brains. Findings showed a significant decrease of lysophosphatidylcholine and phosphatidylethanolamine formed by low levels of polyunsaturated fatty acids (20 : 4, 22 : 6) in AD brains. However, phosphatidylethanolamine-ceramide and phosphoglycerol were significantly increased in SAD, conformed by high levels of (18 : 0/18 : 1) and (30/32/36 : 0/1/2), respectively. Together, the findings suggest a deficiency in lysophosphacholine and phosphatidylethanolamine, and alteration in the balance between poly- and unsaturated fatty acids in both types of AD, and a differential pattern of phospholipid profile and fatty acid composition between E280A FAD and SAD human brains.
ScheltensP, BlennowK, BretelerMM, de StrooperB, FrisoniGB, SallowayS, Van der FlierWM (2016) Alzheimer’s disease. Lancet388, 507–517.
3.
BirdTD (1993) Early-Onset Familial Alzheimer Disease. In Gene Reviews, PagonRA, AdamMP, ArdingerHH, et al. eds. University of Washington, Seattle.
4.
ListaS, O’BryantSE, BlennowK, DuboisB, HugonJ, ZetterbergH, HampelH (2015) Biomarkers in sporadic and familial Alzheimer’s disease. J Alzheimers Dis47, 291–317.
5.
KalvodovaL, KahyaN, SchwilleP, EhehaltR, VerkadeP, DrechselD, SimonsK (2005) Lipids as modulators of proteolytic activity ofBACE: Involvement of cholesterol, glycosphingolipids, and anionicphospholipids in vitro. J Biol Chem280, 36815–36823.
6.
Hirsch-ReinshagenV, BurgessBL, WellingtonCL (2009) Why lipids are important for Alzheimer disease?. Mol Cell Biochem326, 121–129.
7.
DiauGY, HsiehAT, Sarkadi-NagyEA, WijendranV, NathanielszPW, BrennaJT (2005) The influence of long chain polyunsaturate supplementation on docosahexaenoic acid and arachidonic acid in baboon neonate central nervous system. BMC Med3, 11.
8.
BazanNG, MolinaMF, GordonWC (2011) Docosahexaenoic acid signalolipidomics in nutrition: Significance in aging, neuroinflammation, macular degeneration, Alzheimer’s, and other neurodegenerative diseases. Annu Rev Nutr31, 321–351.
9.
BazinetRP, LayeS (2014) Polyunsaturated fatty acids and their metabolites in brain function and disease. Nat Rev Neurosci15, 771–785.
10.
SimopoulosAP (2016) An increase in the omega-6/omega-3 fatty acid ratio increases the risk for obesity. Nutrients8, 128.
11.
RaoJS, ErtleyRN, DeMarJCJr, RapoportSI, BazinetRP, LeeHJ (2007) Dietary n-3 PUFA deprivation alters expression of enzymes of the arachidonic and docosahexaenoic acid cascades in rat frontal cortex. Mol Psychiatry12, 151–157.
12.
Siri-TarinoPW, SunQ, HuFB, KraussRM (2010) Saturated fat, carbohydrate, and cardiovascular disease. Am J Clin Nutr91, 502–509.
13.
LiuJJ, GreenP, MannJJ, RapoportSI, SubletteME (2015) Pathways of polyunsaturated fatty acid utilization: Implications for brain function in neuropsychiatric health and disease. Brain Res1597, 220–246.
BraakH, BraakE (1997) Staging of Alzheimer-related cortical destruction. Int Psychogeriatr9(Suppl 1), 257–272.
16.
GeddesJW, TekirianTL, SoultanianNS, AshfordJW, DavisDG, MarkesberyWR (1997) Comparison of neuropathologic criteria for the diagnosis of Alzheimer’s disease. Neurobiol Aging18, S99–105.
17.
FillenbaumGG, van BelleG, MorrisJC, MohsRC, MirraSS, DavisPC, TariotPN, SilvermanJM, ClarkCM, Welsh-BohmerKA, HeymanA (2008) CERAD (Consortium to Establish a Registry for Alzheimer’s Disease) The first 20 years. Alzheimers Dement4, 96–109.
18.
FolchJ, LeesM, Sloane StanleyGH (1957) A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem226, 497–509.
19.
ZhouZ, MarepallySR, NuneDS, PallakolluP, RaganG, RothMR, WangL, LushingtonGH, VisvanathanM, WeltiR (2011) LipidomeDB data calculation environment: Online processing of direct-infusion mass spectral data for lipid profiles. Lipids46, 879–884.
20.
BarkerM, RayensW (2003) Partial least squares for discrimination. J Chemometrics17, 166–173.
21.
BallabioD, CosonniV (2013) Classification tools in chemistry. Part 1: Linear models. PLS-DA. Anal Methods5, 3790–3798.
22.
MehmoodT, Hovde LilandK, SnipenL, SæbøS (2012) A reviewof variable selection methods in Partial Least Squares Regression. Chemometr Intell Lab Syst118, 62–69.
23.
KhanUA, LiuL, ProvenzanoFA, BermanDE, ProfaciCP, SloanR, MayeuxR, DuffKE, SmallSA (2014) Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer’s disease. Nat Neurosci17, 304–311.
24.
DaviesCA, MannDM, SumpterPQ, YatesPO (1987) A quantitativemorphometric analysis of the neuronal and synaptic content of thefrontal and temporal cortex in patients with Alzheimer’s disease. J Neurol Sci78, 151–164.
25.
ScheffSW, PriceDA (2006) Alzheimer’s disease-related alterations in synaptic density: Neocortex and hippocampus. J Alzheimers Dis9, 101–115.
26.
Di PaoloG, KimTW (2011) Linking lipids to Alzheimer’s disease: Cholesterol and beyond. Nat Rev Neurosci12, 284–296.
27.
ChanRB, OliveiraTG, CortesEP, HonigLS, DuffKE, SmallSA, WenkMR, ShuiG, Di PaoloG (2012) Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J Biol Chem287, 2678–2688.
28.
GeorgeAJ, HolsingerRM, McLeanCA, TanSS, ScottHS, CardamoneT, CappaiR, MastersCL, LiQX (2006) Decreased phosphatidylethanolamine binding protein expression correlates with Abeta accumulation in the Tg2576 mouse model of Alzheimer’s disease. Neurobiol Aging27, 614–623.
29.
DorningerF, BroddeA, BravermanNE, MoserAB, JustWW, Forss-PetterS, BrüggerB, BergerJ (2015) Homeostasis of phospholipids - The level of phosphatidylethanolamine tightly adapts to changes in ethanolamine plasmalogens. Biochim Biophys Acta1851, 117–128.
30.
GinsbergL, RafiqueS, XuerebJH, RapoportSI, GershfeldNL (1995) Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer’s disease brain. Brain Res698, 223–6.
31.
Villamil-OrtizJG, Barrera-OcampoA, PiedrahitaD, Velasquez-RodriguezCM, Arias-LondonoJD, Cardona-GomezGP (2016) BACE1 RNAi restores the composition of phosphatidylethanolamine-derivates related to memory improvement in aged 3xTg-AD mice. Front Cell Neurosci10, 260.
32.
NaudiA, CabreR, JoveM, AyalaV, GonzaloH, Portero-OtinM, FerrerI, PamplonaR (2015) Lipidomics of human brain aging and Alzheimer’s disease pathology. Int Rev Neurobiol122, 133–189.
33.
WhileyL, SenA, HeatonJ, ProitsiP, García-GómezD, LeungR, SmithN, ThambisettyM, KloszewskaI, MecocciP, SoininenH, TsolakiM, VellasB, LovestoneS, Legido-QuigleyC, AddNeuroMed Consortium (2014) Evidence of altered phosphatidylcholinemetabolism in Alzheimer’s disease. Neurobiol Aging35, 271–278.
34.
LeeJCM, SimonyiA, SunAY, SunGY (2011) Phospholipases A2 and neural membrane dynamics: Implications for Alzheimer’s disease. J Neurochem116, 813–819.
35.
SoderbergM, EdlundC, KristenssonK, DallnerG (1991) Fatty acid composition of brain phospholipids in aging and in Alzheimer’s disease. Lipids26, 421–425.
36.
AstaritaG, JungKM, BerchtoldNC, NguyenVQ, GillenDL, HeadE, CotmanCW, PiomelliD (2010) Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer’s disease. PLoS One5, e12538.
37.
CunnaneSC, Chouinard-WatkinsR, CastellanoCA, Barberger-GateauP (2013) Docosahexaenoic acid homeostasis, brain aging and Alzheimer’s disease: Can we reconcile the evidence?Prostaglandins Leukot Essent Fatty Acids88, 61–70.
38.
FarooquiAA (2012) Lipid mediators and their metabolism in thenucleous: Implications for Alzheimer’s disease. J AlzheimersDis30(Suppl 2), S163–178.
39.
QuMH, YangX, WangY, TangQ, HanH, WangJ, WangGD, XueC, GaoZ (2016) Docosahexaenoic acid-phosphatidylcholine improves cognitive deficits in an Abeta23-35-induced Alzheimer’s disease rat model. Curr Top Med Chem16, 558–564.
40.
StonehouseW, ConlonCA, PoddJ, HillSR, MinihaneAM, HaskellC, KennedyD (2013) DHA supplementation improved both memory and reaction time in healthy young adults: A randomized controlled trial. Am J Clin Nutr97, 1134–1143.
BickertA, GinkelC, KolM, vom DorpK, JastrowH, DegenJ, JacobsRL, VanceDE, WinterhagerE, JiangXC, DörmannP, SomerharjuP, HolthuisJC, WilleckeK (2015) Functional characterization of enzymescatalyzing ceramide phosphoethanolamine biosynthesis in mice. J Lipid Res56, 821–835.
46.
HildenbrandtGR, AbrahamT, BieberLL (1971) Metabolism of ceramide phosphorylethanolamine, phosphatidylinositol, phosphatidylserine and phosphatidylglycerol by housefly larvae. Lipids6, 508–516.
47.
VacaruAM, van den DikkenbergJ, TernesP, HolthuisJC (2013) Ceramide phosphoethanolamine biosynthesis in Drosophila is mediated by a unique ethanolamine phosphotransferase in the Golgi lumen. J Biol Chem288, 11520–11530.
48.
MauriceA, MalgatM (1993) Phosphatidylethanolamine: Ceramide-ethanolaminephosphotransferase activity in synaptic plasma membrane vesicles. Influence of some cations and phospholipid environment on transferase activity. Further proof of its location. Int J Biochem25, 1183–1187.
49.
DoroudgarM, LafleurM (2017) Ceramide-C16 is a versatile modulator of phosphatidylethanolamine polymorphism. Biophys J112, 2357–2366.
50.
BartkeN, HannunYA (2009) Bioactive sphingolipids: Metabolism and function. (Suppl), S. J Lipid Res50, 91–96.
51.
VethakanrajHS, BabuTA, SudarsananGB, DuraisamyPK, Ashok KumarS (2015) Targeting ceramide metabolic pathway induces apoptosis in human breast cancer cell lines. Biochem Biophys Res Commun464, 833–839.
52.
PatilS, ChanC (2005) Palmitic and stearic fatty acids induce Alzheimer-like hyperphosphorylation of tau in primary rat cortical neurons. Neurosci Lett384, 288–293.
53.
OsmanC, VoelkerDR, LangerT (2011) Making heads or tails of phospholipids in mitochondria. J Cell Biol192, 7–16.
54.
MurrayNR, FieldsAP (1998) Phosphatidylglycerol is a physiologic activator of nuclear protein kinase C. J Biol Chem273, 11514–11520.
55.
MoritaSY, TeradaT (2015) Enzymatic measurement of phosphatidylglycerol and cardiolipin in cultured cells and mitochondria. Sci Rep5, 11737.
56.
Monteiro-CardosoVF, OliveiraMM, MeloT, DominguesMR, MoreiraPI, FerreiroE, PeixotoF, VideiraRA (2015) Cardiolipin profilechanges are associated to the early synaptic mitochondrialdysfunction in Alzheimer’s disease. J Alzheimers Dis43, 1375–1392.
57.
HorvathSE, DaumG (2013) Lipids of mitochondria. Prog Lipid Res52, 590–614.
58.
WangX, SuB, LeeHG, LiX, PerryG, SmithMA, ZhuX (2009) Impaired balance of mitochondrial fission and fusion in Alzheimer’s disease. J Neurosci29, 9090–9103.
59.
PatilS, ShengL, MasserangA, ChanC (2006) Palmitic acid-treated astrocytes induce BACE1 upregulation and accumulation of C-terminal fragment of APP in primary cortical neurons. Neurosci Lett406, 55–59.
